📊 LONA Key Takeaways
Is LONA a Good Investment? Thesis Analysis
LeonaBio is a pre-revenue development-stage biotech company with -$105.6M net income and -$45.7M operating cash burn, indicating no commercialized products generating meaningful revenue. While the company maintains a strong cash position ($69.3M) with zero debt, at the current burn rate the runway extends only ~1.5 years without additional capital raises, creating material financing risk and execution pressure.
Why Buy LONA? Key Strengths
- Strong cash reserves of $69.3M provide runway for continued R&D
- Zero debt with clean balance sheet (Debt/Equity 0.00x)
- Healthy liquidity position (1.88x current ratio) to meet short-term obligations
LONA Investment Risks to Consider
- Pre-revenue or minimal revenue status with no clear path to profitability demonstrated
- Significant annual cash burn of -$45.7M with persistent operating losses of -$102.3M
- Cash runway exhaustion risk requiring dilutive capital raise within 18-24 months at current burn
- Flat net income improvement YoY (+0.0%) suggests structural burn continues unabated
- Development-stage biotech carries binary product development and commercialization risk
Key Metrics to Watch
- Revenue generation and gross margin upon product commercialization
- Operating cash burn rate trends and impact on runway
- Capital raise activity and dilution impact
- Product development milestones and regulatory approval progress
- Insider transaction patterns for signals of management confidence
LONA Financial Metrics
💡 AI Analyst Insight
LeonaBio, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
LONA Profitability Ratios
LONA vs Healthcare Sector
How LeonaBio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is LONA Overvalued or Undervalued?
Based on fundamental analysis, LeonaBio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
LONA Balance Sheet & Liquidity
LONA 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: LeonaBio, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-25.19 indicates the company is currently unprofitable.
LONA Growth Metrics (YoY)
LONA Capital Allocation
LONA SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for LeonaBio, Inc. (CIK: 0001620463)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LONA
What is the AI rating for LONA?
LeonaBio, Inc. (LONA) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are LONA's key strengths?
Claude: Strong cash reserves of $69.3M provide runway for continued R&D. Zero debt with clean balance sheet (Debt/Equity 0.00x).
What are the risks of investing in LONA?
Claude: Pre-revenue or minimal revenue status with no clear path to profitability demonstrated. Significant annual cash burn of -$45.7M with persistent operating losses of -$102.3M.
What is LONA's revenue and growth?
LeonaBio, Inc. reported revenue of N/A.
Does LONA pay dividends?
LeonaBio, Inc. does not currently pay dividends.
Where can I find LONA SEC filings?
Official SEC filings for LeonaBio, Inc. (CIK: 0001620463) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LONA's EPS?
LeonaBio, Inc. has a diluted EPS of $-24.70.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LONA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, LeonaBio, Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LONA stock overvalued or undervalued?
Valuation metrics for LONA: ROE of -380.0% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LONA stock in 2026?
Our dual AI analysis gives LeonaBio, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LONA's free cash flow?
LeonaBio, Inc.'s operating cash flow is $-45.7M, with capital expenditures of $33.0K.
How does LONA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -380.0% (avg: 15%), current ratio 1.88 (avg: 2).